[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100411865":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":79,"collaborators":26,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":84,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":26,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":66,"whyStopped":26,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hemostatic agent group","EXPERIMENTAL","During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL® Fibrin Sealant, Ethicon, USA), which consist of thrombin and coagulating proteins, mainly fibrinogen and fibronectin. If hemostasis is not fulfilled enough by using it, a additional intervention such as electrocoagulation with bipolar forceps and barbed suture is required to stop bleeding.",[13],"Procedure: Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy",{"label":15,"type":16,"description":17,"interventionNames":18},"Suturing group","ACTIVE_COMPARATOR","During operation, barbed suture will be applied to the inner surface of ovarian parenchyme where ovarian endometriosis was attached. In this group, if bleeding is continued after suturing, additional electrocoagulation with bipolar forceps will be conducted.",[19],"Procedure: suturing with barbed sutures during laparoscopic ovarian cystectomy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy","During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"suturing with barbed sutures during laparoscopic ovarian cystectomy","During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding",[15],[32],{"name":33,"affiliation":5,"role":34},"Hee seung Kim, MD\u002FPhD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Hyunji Lim, MD","CONTACT","82-2-2072-2821","hyunji3292@gmail.com",{"name":33,"role":38,"phone":42,"phoneExt":26,"email":43},"82-2-2072-4863","bboddi0311@gmail.com",[45,65],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":26,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Dongguk University Ilsan Hospital","NOT_YET_RECRUITING","Goyang-si","Gyeonggi-do","10326","South Korea",{"type":53,"coordinates":54},"Point",[55,56],126.835,37.65639,{"lat":56,"lon":55},[59,63],{"name":60,"role":38,"phone":61,"phoneExt":26,"email":62},"Ga Won Yim, MD\u002FPhD","82-31-961-7366","gawonyim@gmail.com",{"name":64,"role":34,"phone":26,"phoneExt":26,"email":26},"Chae Hyeong Lee, MD\u002FPhD",{"facility":5,"status":66,"city":67,"state":26,"zip":26,"country":51,"countryCode":26,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"RECRUITING","Seoul",{"type":53,"coordinates":69},[70,71],126.9784,37.566,{"lat":71,"lon":70},[74,76,78],{"name":37,"role":38,"phone":75,"phoneExt":26,"email":40},"82-2-2072-2643",{"name":77,"role":38,"phone":42,"phoneExt":26,"email":43},"Hee Seung Kim, MD\u002FPhD",{"name":77,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":34,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Hee Seung Kim","associate professor","100411865","comparison-of-hemostatic-agent-to-suture-in-terms-of-hemostatic-function-and-preservation-of-ovarian-function-100411865",false,"NCT04643106","Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function","A Multi-center, Randomized, Investigator-initiated Trial to Evaluate the Efficacy of PRreservation of ovArian Function, Hemostasis, and sAfety of a Hemostatic Agent Versus Suturing During Laparoscopic Ovarian Cystectomy for Endometrioma","PRAHA-2","Inclusion Criteria:\n\n* Informed consent.\n* Age: 19-45 year-old women\n* American Society of Anesthesiologists Physical Status classification 1 or 2\n* Plan of laparoscopic ovarian cystectomy for unilateral or bilateral ovarian endometriosis diagnosed by ultrasonography\n* Regular menstruation every 21-45 days\n\nExclusion Criteria:\n\n* No 'ovarian' endometriosis\n* Suspicious disease of ovarian malignancy\n* Age: 18 and younger, 46 and older\n* Pregnancy or breastfeeding.\n* Lower than 0.05 ng\u002Fml of serum Anti-mullerian hormone level\n* Hormonal therapy within recent 3 months\n* Considered as inappropriate by the researcher's judgment.","FEMALE","19 Years","45 Years",{"count":94,"type":95},90,"ESTIMATED","INTERVENTIONAL",[98],"NA","This study aims to evaluate the efficacy of preservation of ovarian function, hemostasis, and safety of a hemostatic agent versus suturing during laparoscopic ovarian cystectomy for ovarian endometriosis.",[101],"Benign Ovarian Cyst",[103,104,105,106,107,108,109],"endometriosis","endometrioma","ovarian cystectomy","ovarian function","ovarian reserve","hemostatic agent","suture","2023-06-23",{"date":112,"type":113},"2023-06-26","ACTUAL",{"date":115,"type":113},"2021-02-25",{"date":117,"type":95},"2026-12-31",{"name":5,"class":6},2]